Pfizer (NYSE:PFE) received a $40.00 target price from investment analysts at Jefferies Group in a research note issued to investors on Tuesday. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Jefferies Group’s target price suggests a potential upside of 9.44% from the company’s previous close.
PFE has been the subject of a number of other research reports. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. JPMorgan Chase & Co. set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, November 1st. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a report on Tuesday, January 2nd. Morgan Stanley set a $41.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $38.89.
Shares of Pfizer (PFE) opened at $36.55 on Tuesday. Pfizer has a 52-week low of $30.90 and a 52-week high of $37.35. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The company has a market cap of $217,800.00, a P/E ratio of 22.42, a P/E/G ratio of 2.44 and a beta of 1.01.
Pfizer announced that its board has authorized a share buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.
In other news, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock worth $1,065,220 in the last quarter. Company insiders own 0.06% of the company’s stock.
Several large investors have recently added to or reduced their stakes in PFE. Beacon Financial Group grew its position in Pfizer by 2.3% during the second quarter. Beacon Financial Group now owns 228,070 shares of the biopharmaceutical company’s stock valued at $7,670,000 after buying an additional 5,027 shares during the period. First Command Bank grew its position in shares of Pfizer by 131.5% in the second quarter. First Command Bank now owns 23,934 shares of the biopharmaceutical company’s stock valued at $804,000 after purchasing an additional 13,596 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Pfizer in the second quarter valued at about $534,000. Stock Yards Bank & Trust Co. grew its position in shares of Pfizer by 0.7% in the second quarter. Stock Yards Bank & Trust Co. now owns 123,800 shares of the biopharmaceutical company’s stock valued at $4,159,000 after purchasing an additional 832 shares during the period. Finally, Factory Mutual Insurance Co. grew its position in shares of Pfizer by 2.1% in the second quarter. Factory Mutual Insurance Co. now owns 2,935,897 shares of the biopharmaceutical company’s stock valued at $98,617,000 after purchasing an additional 60,000 shares during the period. Hedge funds and other institutional investors own 69.75% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.